Order Article Reprints

Asumda FZ, Campbell NA, Hassan MA, Fathi R, Vasquez Rico DF, Kiem M, Vang EV, Kim YH, Luo X, O’Brien DR, et al. Combined Antitumor Effect of the Serine Protease Urokinase Inhibitor Upamostat and the Sphingosine Kinase 2 Inhibitor Opaganib on Cholangiocarcinoma Patient-Derived Xenografts. Cancers. 2024; 16(5):1050. https://doi.org/10.3390/cancers16051050

Asumda, Faizal Z., Nellie A. Campbell, Mohamed A. Hassan, Reza Fathi, Daniella F. Vasquez Rico, Melanie Kiem, Ethan V. Vang, Yo Han Kim, Xin Luo, Daniel R. O’Brien, and et al. 2024. "Combined Antitumor Effect of the Serine Protease Urokinase Inhibitor Upamostat and the Sphingosine Kinase 2 Inhibitor Opaganib on Cholangiocarcinoma Patient-Derived Xenografts" Cancers 16, no. 5: 1050. https://doi.org/10.3390/cancers16051050

Asumda, F. Z., Campbell, N. A., Hassan, M. A., Fathi, R., Vasquez Rico, D. F., Kiem, M., Vang, E. V., Kim, Y. H., Luo, X., O’Brien, D. R., Buhrow, S. A., Reid, J. M., Moore, M. J., Ben-Yair, V. K., Levitt, M. L., Leiting, J. L., Abdelrahman, A. M., Zhu, X., Lucien, F., ... Roberts, L. R. (2024). Combined Antitumor Effect of the Serine Protease Urokinase Inhibitor Upamostat and the Sphingosine Kinase 2 Inhibitor Opaganib on Cholangiocarcinoma Patient-Derived Xenografts. Cancers, 16(5), 1050. https://doi.org/10.3390/cancers16051050